SOUTH RIDING, Va., Sept. 1, 2020 /PRNewswire-PRWeb/ -- Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and diagnostics companies, has announced the placement of Julianne Averill, CPA, as Chief Financial Officer at Alveo Technologies. Averill will be responsible for leading all financial operations and implementing key business strategies to accelerate Alveo's growth as the company advances its be.well™ platform, a point-of-care and at-home diagnostic tool currently in development.
Averill has more than 18 years of leadership experience in the life sciences, technology, and digital health fields, and has participated in or led more than $2 billion in successful strategic financing and mergers and acquisitions initiatives. She most recently served as Vice President of Finance at BlackThorn Therapeutics, driving strategic growth initiatives and investment strategies. She previously held leadership roles at Manifest MedEx and Starwood Waypoint Residential Trust, and served as an audit manager at Deloitte, working with various Fortune 500 and international entities in the consumer business and life sciences industries.
Founded in 2014, Alveo Technologies is a pre-clinical stage medical diagnostics company headquartered in Alameda, California. It is a leader in developing novel technologies that enable real-time, low-cost, at-home molecular detection of infectious disease.
"Julianne Averill is a highly-respected and accomplished healthcare financial expert with a history of galvanizing strategic growth and formulating innovative business strategies throughout an organization," said Slone Partners President Tara Kochis-Stach. "She brings tremendous passion, vision, and aptitude, and will make an excellent addition to the Alveo leadership team as the company becomes even more strongly positioned in a competitive marketplace."
"Julianne's strong track record of driving results and accelerating growth comes at a critical time as the U.S. enters the twindemic COVID and flu season," said Ron Chiarello, Ph.D., Chairman, CEO, and Founder of Alveo. "As Alveo continues its initiative of bringing accurate, at-home testing solutions to market, Julianne's strong financial expertise will be a valuable asset to the leadership team, ensuring we remain poised for long-term success."
"I was instantly drawn to Alveo's vision of putting an affordable, rapid at-home diagnostic tool for infectious diseases into the hands of consumers worldwide," said Averill. "Alveo has a strong leadership team, a unique solution, and tremendous potential. I am thrilled to be joining the company at this exciting stage of its development. I look forward to leveraging my experience to help drive growth at Alveo as it continues on the trajectory of transforming the way infectious diseases are detected and managed."
Averill earned a BS in Business Administration and a Master's in Accounting at California State University, Fresno. She also earned a certificate from the Harvard Business Analytics Program in January 2020.
ABOUT SLONE PARTNERS
Slone Partners delivers the leaders who build amazing scientific healthcare organizations – People Are Our Science®. Since 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established life sciences, biotech, diagnostics, precision medicine, CRO, and laboratory services companies. With coast-to-coast presence in the most active healthcare industry hubs of Boston, San Francisco, New York, Los Angeles, San Diego, Austin, Research Triangle Park NC, and Washington DC, Slone Partners uniquely and precisely provides an array of executive search and advisory services to innovative scientific healthcare companies. To learn more about Slone Partners' value proposition and processes, visit http://www.slonepartners.com or call 888.784.3422.
ABOUT ALVEO TECHNOLOGIES
Alveo Technologies is leading the transformation of the consumer health tech market with a low-cost, easy-to-use, at-home diagnostic platform that will change the way infectious diseases are detected and managed. The company's be.well™ testing system gives individuals access to cutting-edge molecular testing and cloud-based data analytics for rapid diagnosis and management of infectious diseases. With an initial focus on acute respiratory infections, including COVID-19, Influenza A/B, and RSV, Alveo's agile and dynamic diagnostic platform can be adapted to detect a wide range of diseases that threaten public health. Affordable access to real-time, at-home results will transform the way individuals, healthcare providers, and public health professionals identify and manage disease outbreaks. To learn more, visit https://alveotechnologies.com/.
SOURCE Slone Partners
Share this article